StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant cash

Cash and short-term investments held at the end of each period.

Immunovant's cash was $797.80M at Jun 30, 2026. For fiscal 2026 it was $902.11M, up 26.4% from the year before. The highest annual figure on record is $902.11M in fiscal 2026.

Annual cash

PeriodPeriod endValueChange
FY2026Mar 31, 2026$902.11M+26.4%
FY2025Mar 31, 2025$713.97M+12.4%
FY2024Mar 31, 2024$635.37M+68.7%
FY2023Mar 31, 2023$376.53M-23.8%
FY2022Mar 31, 2022$493.82M+23.4%
FY2021Mar 31, 2021$400.15M+297.9%
FY2020Mar 31, 2020$100.57M+1339.8%
FY2019Mar 31, 2019$6.99M–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$797.80M+33.2%
Q4 FY2026CQ1 2026Mar 31, 2026$902.11M+26.4%
Q3 FY2026CQ4 2025Dec 31, 2025$994.53M+165.4%
Q2 FY2026CQ3 2025Sep 30, 2025$521.87M+10.3%
Q1 FY2026CQ2 2025Jun 30, 2025$598.91M+6.9%
Q4 FY2025CQ1 2025Mar 31, 2025$713.97M+12.4%
Q3 FY2025CQ4 2024Dec 31, 2024$374.69M-45.8%
Q2 FY2025CQ3 2024Sep 30, 2024$472.94M+75.2%
Q1 FY2025CQ2 2024Jun 30, 2024$560.01M+69.7%
Q4 FY2024CQ1 2024Mar 31, 2024$635.37M+68.7%
Q3 FY2024CQ4 2023Dec 31, 2023$690.94M+59.7%
Q2 FY2024CQ3 2023Sep 30, 2023$269.93M-33.5%
Q1 FY2024CQ2 2023Jun 30, 2023$329.96M-22.8%
Q4 FY2023CQ1 2023Mar 31, 2023$376.53M-23.8%
Q3 FY2023CQ4 2022Dec 31, 2022$432.61M-17.9%
Q2 FY2023CQ3 2022Sep 30, 2022$405.77M-27.4%
Q1 FY2023CQ2 2022Jun 30, 2022$427.21M+12.7%
Q4 FY2022CQ1 2022Mar 31, 2022$493.82M+23.4%
Q3 FY2022CQ4 2021Dec 31, 2021$527.00M+24.9%
Q2 FY2022CQ3 2021Sep 30, 2021$558.95M+25.8%
Q1 FY2022CQ2 2021Jun 30, 2021$379.01M+35.2%
Q4 FY2021CQ1 2021Mar 31, 2021$400.15M+297.9%
Q3 FY2021CQ4 2020Dec 31, 2020$421.97M+2121.9%
Q2 FY2021CQ3 2020Sep 30, 2020$444.37M+11132.9%
Q1 FY2021CQ2 2020Jun 30, 2020$280.28M+3912.6%
Q4 FY2020CQ1 2020Mar 31, 2020$100.57M+731.0%
Q3 FY2020CQ4 2018Sep 30, 2019$18.99M–
Q1 FY2020CQ2 2019Jun 30, 2019$3.96M–
Q4 FY2019CQ1 2019Mar 31, 2019$6.99M–
Q3 FY2019CQ4 2018Dec 31, 2018$12.10M–

More Immunovant figures

See a number that looks wrong?